Pfizer COVID-19 vaccine cuts symptomatic cases by 94%, data shows

COVID-19 infections fell by 94 percent among people who received two doses of Pfizer's vaccine, according to a study by Clalit, the largest healthcare provider in Israel.

Clalit studied symptomatic COVID-19 infections among 600,000 people who received two doses of Pfizer's vaccine and compared them to an unvaccinated group of the same size, The Wall Street Journal reported Feb. 15. The study included 430,000 participants between ages 16 and 59 and 170,000 participants ages 60 and older, Clalit said.

The study also found that Pfizer's vaccine reduced cases of severe illness from COVID-19 by 92 percent, according to The Wall Street Journal.

More articles on pharmacy:
36% of Americans forgo medications to pay for essentials, survey says
Sanofi COVID-19 vaccine will not be ready this year, CEO says
Small pharmacies struggling to obtain reimbursement for COVID-19 vaccine administration


Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Whitepapers

Featured Webinars